X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE WOCKHARDT LTD. TTK HEALTHCARE/
WOCKHARDT LTD.
 
P/E (TTM) x 50.0 -15.8 - View Chart
P/BV x 9.2 2.6 355.4% View Chart
Dividend Yield % 0.3 1.3 24.8%  

Financials

 TTK HEALTHCARE   WOCKHARDT LTD.
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
WOCKHARDT LTD.
Mar-17
TTK HEALTHCARE/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs6631,129 58.8%   
Low Rs399627 63.6%   
Sales per share (Unadj.) Rs535.6363.1 147.5%  
Earnings per share (Unadj.) Rs15.9-20.4 -78.0%  
Cash flow per share (Unadj.) Rs20.0-7.0 -287.1%  
Dividends per share (Unadj.) Rs4.0010.00 40.0%  
Dividend yield (eoy) %0.81.1 66.1%  
Book value per share (Unadj.) Rs137.6301.8 45.6%  
Shares outstanding (eoy) m7.77110.55 7.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.02.4 41.0%   
Avg P/E ratio x33.3-42.9 -77.6%  
P/CF ratio (eoy) x26.5-125.9 -21.1%  
Price / Book Value ratio x3.92.9 132.7%  
Dividend payout %25.1-48.9 -51.3%   
Avg Mkt Cap Rs m4,12797,063 4.3%   
No. of employees `0001.76.8 25.2%   
Total wages/salary Rs m6079,665 6.3%   
Avg. sales/employee Rs Th2,436.75,931.8 41.1%   
Avg. wages/employee Rs Th355.21,428.1 24.9%   
Avg. net profit/employee Rs Th72.5-334.0 -21.7%   
INCOME DATA
Net Sales Rs m4,16240,146 10.4%  
Other income Rs m611,143 5.4%   
Total revenues Rs m4,22341,289 10.2%   
Gross profit Rs m197128 154.0%  
Depreciation Rs m321,489 2.1%   
Interest Rs m302,253 1.3%   
Profit before tax Rs m197-2,472 -8.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m73-211 -34.5%   
Profit after tax Rs m124-2,260 -5.5%  
Gross profit margin %4.70.3 1,485.4%  
Effective tax rate %37.08.5 433.3%   
Net profit margin %3.0-5.6 -52.9%  
BALANCE SHEET DATA
Current assets Rs m1,62946,160 3.5%   
Current liabilities Rs m1,05819,258 5.5%   
Net working cap to sales %13.767.0 20.5%  
Current ratio x1.52.4 64.2%  
Inventory Days Days30101 29.6%  
Debtors Days Days3494 35.7%  
Net fixed assets Rs m55640,165 1.4%   
Share capital Rs m78553 14.1%   
"Free" reserves Rs m87832,814 2.7%   
Net worth Rs m1,06933,367 3.2%   
Long term debt Rs m15931,903 0.5%   
Total assets Rs m2,39989,687 2.7%  
Interest coverage x7.6-0.1 -7,802.7%   
Debt to equity ratio x0.11.0 15.5%  
Sales to assets ratio x1.70.4 387.5%   
Return on assets %6.40 -74,660.7%  
Return on equity %11.6-6.8 -171.0%  
Return on capital %18.5-0.3 -5,504.6%  
Exports to sales %0.80-   
Imports to sales %1.40-   
Exports (fob) Rs m33NA-   
Imports (cif) Rs m58NA-   
Fx inflow Rs m339,121 0.4%   
Fx outflow Rs m632,133 3.0%   
Net fx Rs m-306,988 -0.4%   
CASH FLOW
From Operations Rs m127-2,695 -4.7%  
From Investments Rs m-146-6,863 2.1%  
From Financial Activity Rs m2212,545 0.2%  
Net Cashflow Rs m33,010 0.1%  

Share Holding

Indian Promoters % 65.4 74.5 87.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.3 160.9%  
FIIs % 5.2 7.7 67.5%  
ADR/GDR % 0.0 0.1 -  
Free float % 25.8 15.4 167.5%  
Shareholders   12,723 67,757 18.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare TTK HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Feb 23, 2018 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE - GLENMARK PHARMA COMPARISON

COMPARE TTK HEALTHCARE WITH

MARKET STATS